192 related articles for article (PubMed ID: 27641789)
21. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
Sun M; Karakiewicz PI; Trinh QD
Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
[No Abstract] [Full Text] [Related]
22. Re: Christian Bolenz, Stephen J. Freedland, Brent K. Hollenbeck, et al. costs of radical prostatectomy for prostate cancer: a systematic review. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.059.
Rassweiler J
Eur Urol; 2013 Apr; 63(4):e53-6. PubMed ID: 23312570
[No Abstract] [Full Text] [Related]
23. Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
Alongi F; Aiello D; Mazzola R; Cavalleri S
Eur Urol; 2017 Aug; 72(2):e39-e40. PubMed ID: 28318727
[No Abstract] [Full Text] [Related]
24. Reply to Glen Denmer Santok and Koon Ho Rha's Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023.
Stattin P; Bratt O
Eur Urol; 2017 Apr; 71(4):e115-e116. PubMed ID: 27720538
[No Abstract] [Full Text] [Related]
25. Re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.02.002.
Ates F; Akyol I; Soydan H
Eur Urol; 2012 Jul; 62(1):e9; author reply e10-1. PubMed ID: 22512903
[No Abstract] [Full Text] [Related]
26. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796380
[No Abstract] [Full Text] [Related]
27. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S; Ye H; Lis RT; Sowalsky AG
Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
[No Abstract] [Full Text] [Related]
28. Reply to Michael Froehner and Manfred P. Wirth's letter to the editor re: Vincenzo Ficarra, Giacomo Novara, Raymond C. Rosen, et al. systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405-17.
Ficarra V; Novara G; Mottrie A; Wilson TG; Zattoni F; Montorsi F
Eur Urol; 2013 Mar; 63(3):e39-40. PubMed ID: 23201467
[No Abstract] [Full Text] [Related]
29. Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
Froehner M; Koch R; Wirth MP
Eur Urol; 2015 Nov; 68(5):e103. PubMed ID: 26318708
[No Abstract] [Full Text] [Related]
30. Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
Groenendijk FH; Fransen van de Putte EE; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2015 Aug; 68(2):e33-4. PubMed ID: 25776733
[No Abstract] [Full Text] [Related]
31. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono JS
Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
[No Abstract] [Full Text] [Related]
32. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono J
Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
[No Abstract] [Full Text] [Related]
33. Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
Joniau S; Van den Bergh L
Eur Urol; 2013 Feb; 63(2):e21-2. PubMed ID: 23149147
[No Abstract] [Full Text] [Related]
34. Reply to Nadir I. Osman, Christopher R. Chapple, Sheila MacNeil's Letter to the Editor re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.043.
Barbagli G; Lazzeri M
Eur Urol; 2015 Nov; 68(5):e101-2. PubMed ID: 26260002
[No Abstract] [Full Text] [Related]
35. Re: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.12.052.
Williams SB; Ward JF
Eur Urol; 2016 Sep; 70(3):e77-8. PubMed ID: 26988610
[No Abstract] [Full Text] [Related]
36. Re: Carlo A. Bravi, Marco Paciotti, Eleonora Balestrazzi, et al. Outcomes of Robot-assisted Radical Prostatectomy with the Hugo RAS Surgical System: Initial Experience at a High-volume Robotic Center. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.01.008.
Sarchi L; Sighinolfi MC; Assumma S; Calcagnile T; Grasso A; Sangalli M; Turri F; dell'Orto P; Rocco B
Eur Urol Focus; 2023 Sep; 9(5):844-845. PubMed ID: 36906482
[No Abstract] [Full Text] [Related]
37. Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto's Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.039.
Williams SB; Jubber I; Catto JWF; Daneshmand S
Eur Urol; 2020 Nov; 78(5):e190-e191. PubMed ID: 32838998
[No Abstract] [Full Text] [Related]
38. Reply to Federico Gheza, Simone Crivellaro, and Gian Luca Baiocchi's Letter to the Editor re: Lee C. Zhao, Aaron C. Weinberg, Ziho Lee, et al. Robotic Ureteral Reconstruction Using Buccal Mucosa Grafts: A Multi-institutional Experience. Eur Urol 2018;73:419-26. Robotic Ureteral Reconstruction with Buccal Mucosal Graft: A Call Not To Lose Momentum.
Weinberg A; Zhao L
Eur Urol; 2018 May; 73(5):e129. PubMed ID: 29458982
[No Abstract] [Full Text] [Related]
39. Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.
Cavillon A; Porcher R; Filleron T
Eur Urol; 2023 Jul; 84(1):e22-e23. PubMed ID: 37120335
[No Abstract] [Full Text] [Related]
40. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
